TG’s Follicular Lymphoma Data Suggest Umbralisib Could Succeed In PI3K Delta Class

 
• By Joseph Haas

Overall survival data from a follicular lymphoma cohort of its umbrella NHL study indicate umbralisib could match other PI3K delta inhibitors’ efficacy with better safety/tolerability profile.

Follicular lymphoma is one of mature B-cell neoplasm
TG Therapeutics hopes it can provide a safer, more tolerable follicular lymphoma therapy

More from Clinical Trials

More from R&D